Literature DB >> 7380536

Biphasic protection against bacterial infection in mice induced by vaccination of Propionibacterium acnes.

F Kobayashi, T Nagoya, T Koshi, Y Saino.   

Abstract

A single intraperitoneal injection of the phenol-treated cells of Propionibacterium acnes into mice showed nonspecific resistance against subsequent lethal doses of an intraperitoneal challenge of Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes. The protection showed a biphasic pattern. The maximum protection, designated as the early phase protection, was seen in mice injected with P. acnes vaccine 1 to 2 days before the challenge, whereas the late phase protection was seen in mice vaccinated 16 to 22 days before the challenge. The activity of the reticuloendothelial system in mice after vaccination also showed a biphasic pattern with the peak on days 4 and 12. The delayed activation of the reticuloendothelial system lasted up to 3 weeks and coincided with the period of the late phase protection. The early phase resistance was markedly impaired by the treatment with hydrocortisone and carrageenan, but not by the treatment with anti-thymocyte serum, actinomycin D, or cyclophosphamide. The number of peritoneal polymorphonuclear leukocytes in vaccinated mice increased on days 1 to 2. The number of macrophages also increased at 2 to 21 days after vaccination and reached its maximum on day 14. Total activities of acid phosphatase, Nitro Blue Tetrazolium reduction, and the phagocytic activities of peritoneal exudate cells were also enhanced on and after day 1 after the injection of P. acnes vaccine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7380536      PMCID: PMC550777          DOI: 10.1128/iai.27.2.391-396.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Mechanisms of macrophage activation by corynebacterium parvum. II. In vivo experiments.

Authors:  R Bomford; G H Christie
Journal:  Cell Immunol       Date:  1975-05       Impact factor: 4.868

2.  Quantitative nitroblue tetrazolium test in chronic granulomatous disease.

Authors:  R L Baehner; D G Nathan
Journal:  N Engl J Med       Date:  1968-05-02       Impact factor: 91.245

3.  The effect of carrageenan on delayed hypersensitivity reactions.

Authors:  H J Schwartz; S Leskowitz
Journal:  J Immunol       Date:  1969-07       Impact factor: 5.422

4.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

5.  Enhanced resistance of mice to infection with bacteria following pre-treatment with Corynebacterium parvum.

Authors:  C Adlam; E S Broughton; M T Scott
Journal:  Nat New Biol       Date:  1972-02-16

6.  The role of anaerobic coryneforms on specific and non-specific immunological reactions. I. Effect on particle clearance and humoral and cell-mediated immunological responses.

Authors:  G J O'Neill; D C Henderson; R G White
Journal:  Immunology       Date:  1973-06       Impact factor: 7.397

7.  Differential effect of heterologous anti-lymphocyte serum on antibody-producing cells and antigen-sensitive cells.

Authors:  G Möller; C Zukoski
Journal:  J Immunol       Date:  1968-08       Impact factor: 5.422

8.  Increased nonspecific resstance to malaria produced by administration of killed Corynebacterium parvum.

Authors:  R S Nussenzweig
Journal:  Exp Parasitol       Date:  1967-10       Impact factor: 2.011

9.  Requirement for bone marrow-derived cells in resistance to Listeria.

Authors:  P A Campbell; B L Martens; H R Cooper; J K McClatchy
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

10.  Effect of Corynebacterium parvum on the course of a Listeria monocytogenes infection in normal and congenitally athymic (nude) mice.

Authors:  E J Ruittenberg; L M van Noorle Jansen
Journal:  Zentralbl Bakteriol Orig A       Date:  1975
View more
  7 in total

1.  Enhancement of host resistance against Listeria infection by Lactobacillus casei: role of macrophages.

Authors:  K Sato
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

2.  Antibodies elicited by inactivated propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris.

Authors:  Teruaki Nakatsuji; Yu-Tsueng Liu; Cheng-Po Huang; Christos C Zoubouis; Richard L Gallo; Chun-Ming Huang
Journal:  J Invest Dermatol       Date:  2008-05-08       Impact factor: 8.551

3.  Genetic control of Propionibacterium acnes-induced protection of mice against Babesia microti.

Authors:  P R Wood; I A Clark
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

4.  Enhancement of natural resistance to influenza virus in lipopolysaccharide-responsive and -nonresponsive mice by Propionibacterium acnes.

Authors:  J D Gangemi; J A Hightower; R A Jackson; M H Maher; M G Welsh; M M Sigel
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

5.  Propionibacterium acnes CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment.

Authors:  Teruaki Nakatsuji; De-chu C Tang; Liangfang Zhang; Richard L Gallo; Chun-Ming Huang
Journal:  PLoS One       Date:  2011-04-12       Impact factor: 3.240

6.  TLR9-dependent and independent pathways drive activation of the immune system by Propionibacterium acnes.

Authors:  Sandrine Tchaptchet; Marina Gumenscheimer; Christoph Kalis; Nikolaus Freudenberg; Christoph Hölscher; Carsten J Kirschning; Marinus Lamers; Chris Galanos; Marina A Freudenberg
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

7.  Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris.

Authors:  Teruaki Nakatsuji; Yu-Tsueng Liu; Cheng-Po Huang; Christos C Zouboulis; Richard L Gallo; Chun-Ming Huang
Journal:  PLoS One       Date:  2008-02-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.